While the investment banking world does its best to sing the virtues and likelihood of biotech consolidation, the industry isn't paying attention.
Indeed, perhaps the most interesting aspect of Johnson & Johnson 's acquisition of Scios Inc. [See Deal] isn't...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?